Apple Watch Blood Sugar Monitoring: What's Real vs Hype

The Promise That's Been 'Coming Soon' for Years

Few topics generate more excitement — and more frustration — in the diabetes community than the idea of checking blood sugar through a smartwatch without needles, sensors, or finger pricks. Apple Watch has been at the center of this conversation for years, with rumors of an integrated glucose monitor surfacing in tech media with remarkable regularity. But in 2025, the honest answer remains the same: no Apple Watch currently sold can measure blood glucose. Understanding why requires a brief look at the science, the competition, and what legitimate progress has actually been made.

The Science Behind Noninvasive Glucose Monitoring

The most widely pursued approach for wrist-based glucose sensing is near-infrared (NIR) spectroscopy — shining light through the skin and analyzing how glucose molecules absorb that light. In theory, different glucose concentrations absorb light differently, producing a measurable signal. In practice, the skin is a notoriously complex optical environment. Water, fat, collagen, melanin, and hemoglobin all absorb NIR light, creating overwhelming background noise that obscures the relatively small glucose signal. Motion artifacts, skin temperature, sweat, and even how tightly a watch sits on the wrist introduce further variability.

A 2023 review published in Nature Reviews Bioengineering by Lih Shiuan Tan and colleagues underscored these challenges, noting that no noninvasive optical glucose sensor had yet met the accuracy standards required by the FDA for clinical decision-making — specifically the ISO 15197:2013 standard that requires 95% of readings to fall within ±15 mg/dL of true glucose values below 100 mg/dL, or within ±15% above 100 mg/dL.

What Apple Is Actually Working On

Apple has not publicly announced a glucose monitoring feature, but investigative reporting — including a detailed 2023 Bloomberg report by Mark Gurman — revealed that Apple has operated a secretive team called the Exploratory Design Group working on noninvasive glucose sensing for over a decade. The project, reportedly using photonic chip technology and NIR spectroscopy, had reportedly reached a milestone of proof-of-concept accuracy in controlled settings by late 2023. However, Gurman and other credible sources characterized this as still years away from a consumer product, with 2025 being a development checkpoint rather than a launch window.

Separately, Apple acquired the photonics company RareCyte and has held patents referencing optical sensing architectures consistent with glucose detection — though patents do not equal products.

The Real Competition: Who's Closer?

Several companies are further along than Apple in the public record:

• Dexcom and Abbott dominate the current continuous glucose monitoring (CGM) market with FDA-cleared implantable sensors (Dexcom G7, Abbott Libre 3). These require a small filament under the skin but offer real, validated, FDA-cleared glucose data. Many patients access these through suppliers listed at mdsdiabetes.com.
• Samsung has been testing noninvasive glucose sensing in its Galaxy Watch line and filed for regulatory review in South Korea in 2024, though the technology is reported to measure glucose trends rather than absolute values — a meaningful but important distinction.
• Know Labs (formerly U.S. Patent Holdings) is developing a radio-frequency spectroscopy approach called the Bio-RFID sensor and has published early feasibility data, though large-scale clinical validation remains incomplete.
• Rockley Photonics, which supplies photonic chip components and once had a partnership with Apple, published clinical feasibility data for NIR-based biomarker sensing, but the company faced financial difficulties and restructured in 2023.

Current Status (2025)

As of 2025, here is where things actually stand:

• No Apple Watch model measures blood glucose. Apple Watch Series 9, Ultra 2, and Series 10 do not include any glucose sensing capability.
• No wrist-worn consumer device has FDA clearance for blood glucose monitoring.
• Apple's internal project is progressing but is widely estimated to be 3–5 years from a consumer product at minimum, contingent on solving the accuracy problem and navigating FDA De Novo or PMA pathways.
• Samsung's Galaxy Watch glucose feature, if cleared, would likely measure relative trends rather than absolute mg/dL values — potentially useful but not a replacement for CGMs.
• Patients can search ClinicalTrials.gov using terms like "noninvasive glucose" or "wearable glucose" to find active studies recruiting participants.

Timeline: When Might This Arrive?

Realistic estimates from engineers and regulatory experts cluster around 2028–2030 for a consumer Apple Watch with clinically meaningful glucose monitoring, assuming the accuracy barriers are solved. A more limited "trend" feature could potentially arrive sooner on competing platforms, possibly 2026–2027, though regulatory pathway timelines are unpredictable. Any device claiming to measure blood glucose in the US will require FDA clearance — a bar that has not yet been cleared by any wrist-worn consumer product.

What This Means for Patients

If you have Type 1 or Type 2 diabetes today, the most effective noninvasive-style monitoring available remains the current generation of CGMs from Dexcom and Abbott, both of which require only a tiny under-skin sensor rather than finger-prick blood. These devices are FDA-cleared, covered by most insurance plans, and available through diabetes supply specialists. The gap between a CGM and a truly needle-free watch-based sensor is still real — but the current CGMs are genuinely transformative technology that exists now. Don't delay optimizing your glucose management waiting for a feature that remains years away. Talk to your care team about whether a CGM is right for you, and explore current supply options at mdsdiabetes.com.